济南痛风的症状和饮食(济南发表怎样治痛风比较好) (今日更新中)

BEIJING, Nov. 9 (Xinhuanet) -- Routine bowel screening can cut deaths from bowel cancer by 27 percent, a latest Scottish study finds.The result was presented at the National Cancer Research Institute's (NCRI) conference in Liverpool. Funded by the Scottish government's health department, the study involved over 370,000 people aged 50 to 69 from Scotland. Every participant was given a FOBt (faecal occult blood test) kit-- which was used to collect their stool samples-- every two years between 2000 and 2007. The samples were sent to a laboratory for hidden traces of blood test.Under the monitor of the researchers, the participants saw a 27 percent fewer bowel cancer deaths than a similar number of people from Scotland uninvolved in the trial."For the first time, we can see the effects of an FOBt-based colorectal cancer screening program in the real world of the NHS," cheered author Robert Steele from the Bowel Screening Research Centre in Dundee.According to a BBC report, when bowel cancer is detected at the earliest stage, 90% of patients survive for at least five years. After the disease has spread, the survival rate is just 6%.

BEIJING, Dec. 14 (Xinhua) -- China's new yuan-denominated lending in November rose 7.8 billion yuan (1.2 billion U.S. dollars) year-on-year to 562.2 billion yuan, the People's Bank of China, the central bank (PBOC), announced Wednesday.New loans in the month were smaller compared to that in October, which stood at 586.8 billion yuan.By the end of November, the outstanding broad money supply (M2), which covers cash in circulation and all deposits, rose 12.7 percent year-on-year to 82.55 trillion yuan, according to data released by the PBOC.Meanwhile, the narrow measure of money supply (M1), which covers cash in circulation plus demand deposits, increased 7.8 percent year-on-year to 28.14 trillion yuan by the end of last month, the figures showed.New yuan deposits last month fell sharply to 324.7 billion yuan, down 262.6 billion yuan year-on-year. Outstanding yuan-denominated deposits totaled 79.51 trillion yuan as of the end of last month, up 13.1 percent year-on-year, however, the growth rate was 6.5 percentage points lower compared to the same period last year.Meanwhile, outstanding foreign currencies-denominated deposits stood at 266.8 billion U.S. dollars, up 12.9 percent year-on-year. New deposits of foreign currencies rose 4.1 billion U.S. dollars year-on-year.

WASHINGTON, Nov. 16 (Xinhua) -- Supervised exercise was shown to be more effective than stenting or medication for improved walking ability in patients with peripheral artery disease (PAD), according to a U.S. study reported Wednesday at the 2011 American Heart Association Scientific Sessions meeting.The research group reported that of 111 patients studied in the randomized trial, the most effective treatment proved to be supervised exercise based on the results of a treadmill test taken at baseline and again at six months. Patients who were in the supervised exercise group improved by a mean of 4.6 minutes in the treadmill test, while the group who received stents improved by a mean of 2.5 minutes. However, researchers found that self-reported quality of life measurements proved to be higher in the group that received stents, even though their ability to walk did not improve as greatly as the group that received supervised exercise rehabilitation.The findings were published in the November issue of the journal Circulation. The researchers believe that more studies are necessary, although supervised exercise may be an effective treatment recommended for PAD patients with claudication.PAD is a condition in which plaque builds up in the arteries and affects blood flow, especially to the legs. It is estimated that between 10 and 12 million people suffer from PAD in the United States. One symptom of PAD is known as claudication, a painful cramping of the leg muscles that limits the patient's ability to walk. It affects nearly 2 million people who suffer from PAD, and results in a sedentary lifestyle and poor quality of life.Current U.S. guidelines for the treatment of claudication include pharmacotherapy, supervised exercise rehabilitation and lower extremity revascularization using stents.

OTTAWA, Oct. 3 (Xinhua) -- Many friends and colleagues of Canadian scientist Ralph Steinman reacted with shock when they learned on Monday that Steinman won the Nobel Prize for Medicine and Physiology three days after he died.Since 1974, Nobel Prizes are no longer awarded posthumously, but the Nobel Prize committee said that it had made its choice before Steinman's death.Many of Steinman's friends and colleagues said that they learned of Steinman's death at the same time that they learned of his Nobel Prize, which was awarded for a discovery Steinman made in 1973.Steinman, 68, discovered dendritic cells, which help regulate adaptive immunity, which purges invading microorganisms from the body. Dendritic cells activate T cells, which "remember" the DNA sequence of invading organisms and protect the body from later infections from the same disease."Their work has opened up new avenues for the development of prevention and therapy against infections, cancer and inflammatory disease," the citation said.Monday, the Nobel Committee defended its decision to award the prize to Steinman. "The decision to award the Nobel Prize to Ralph Steinman was made in good faith, based on the assumption that the Nobel Laureate was alive," the foundation said in a statement."The Nobel Foundation thus believes that what has occurred is more reminiscent of the example in the statutes concerning a person who has been named as a Nobel Laureate and has died before the actual Nobel Prize Award Ceremony."It is still unclear who will pick up Steinman's prize at the award ceremony later this year.Steinman, a cell biologist at Rockefeller University in New York City, died of pancreatic cancer on Friday. For more than four years, he had used his own immune therapy discoveries to extend his life."The news is bittersweet, as we also learned this morning from Ralph's family that he passed a few days ago," Rockefeller University President Marc Tessier-Lavigne said in a statement."We are all so touched that our father's many years of hard work are being recognized with a Nobel Prize," Steinman's daughter, Alexis, said in the statement. "He devoted his life to his work and his family, and he would be truly honored."Steinman's heirs will share the 1.5-million U.S. dollar prize with American genetics professor Bruce Beutler and French scientist Jules Hoffmann.Dr. Beutler is professor of genetics and immunology at The Scripps Research Institute in La Jolla, California. Dr. Hoffmann headed a research laboratory in Strasbourg, France, between 1974 and 2009 and served as president of the French National Academy of Sciences between 2007 and 2008."Ralph worked right up until last week," said Michel Nussenzweig, a collaborator of Steinman's at Rockefeller University. "His dream was to use his discovery to cure cancer and infectious diseases like HIV and tuberculosis. It's a dream that's pretty close."Steinman was born in 1943 in Montreal, Canada's second largest city, and studied chemistry and biology at McGill University in his hometown before receiving an MD from Harvard Medical School in Boston in 1968. He joined Rockefeller University in 1970 as a postdoctoral fellow."He was diagnosed with pancreatic cancer four years ago, and his life was extended using a dendritic-cell based immunotherapy of his own design," the university said in a statement.In a statement, Canadian Prime Minister Stephen Harper lauded the three winners of the Nobel for medicine and called the award " a fitting final tribute" to Steinman's life's work."Dr. Steinman shall be honored for all time with this achievement," Harper said. "Canadians will mourn his loss."

BEIJING, Oct. 11 (Xinhuanet) -- An experimental drug that can remove amyloid plaques from the brains of Alzheimer's patients is being developed by Swiss Roche Holding AG in a small early-stage study, according to a report published in the Archives of Neurology on Monday.Researchers suspect the build-up of such plaques may be a cause of the memory robbing disease, although that theory has yet to be definitively proved. Gantenerumab, a biotech drug designed to bind to amyloid plaques in the brain and remove them, is being targeted at the early stages of Alzheimer's with the hope it can slow progression of the disease while patients are still able to function.The Phase I study of 16 Alzheimer's patients tested gantenerumab at two doses against a placebo over six months of treatment.The Roche drug led to a dose-dependent reduction of brain amyloid, while amyloid load increased in patients receiving a placebo, the report said.The next step will be to investigate whether removal of brain amyloid translates into clinical benefit for patients at doses of the experimental drug that are well tolerated and safe, the report said.Much larger trials and further study will be needed to fully understand how gantenerumab works and whether it can stave off Alzheimer's, said the report.Roche is approaching the disease far earlier because amyloid accumulates for 15 years before dementi.

来源：资阳报